Kymera Therapeutics Plans KT-621 BROADEN2 Atopic Dermatitis And BREADTH Asthma Phase 2b Trials Following FDA Fast Track Designation

Benzinga·12/11/2025 12:07:22

語音播報

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial
KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26